A302QUANTITATIVE RISK REDUCTION THROUGH EPICUTANEOUS IMMUNOTHERAPY (EPIT): RESULTS FROM THE PEPITES PHASE III TRIAL
References (0)
Cited by (0)
Copyright © 2018 Published by Elsevier Inc.